Fiona Stapleton News Today

-- Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials --TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre...

Press release content from Business Wire. The AP news staff was not involved in its creation.

US venture capital firm makes $221m investment in Octopus Deploy US venture capital firm makes $221m investment in Octopus Deploy Share Firm: Thomson Geer (Octopus Deploy). Deal: Octopus Deploy has secured an investment from Insight Partners. Value: $221 million. "); googletag.cmd.push(function() { googletag.display(div-gpt-ad-1606778613657-0); }); } Area: Finance. Key players: The Thomson Geer team comprised of partner David Schiavello, partner Peta Thompson, s...

Date Time Revolutionary eye drop trial starts for common eye diseases Research conducted by UNSW Sydney has paved the way for clinical testing of an eye drop treatment for diabetic macular oedema and wet age-related macular degeneration, the leading causes of blindness in the developed world. A clinical trial has commenced across Australia for a novel eye drop treatment that could improve the treatment of patients with retinal vascular diseases. If successful, the eye drops will revolutionise t...

Azura Ophthalmics Announces Primary Endpoints Met in Topline Results from Phase 2 Trial of the Company’s Investigational Treatment for Contact Lens Discomfort Significant improvement in multiple measures of Meibomian gland secretion and associated improvements in contact lens wear time TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today a...